Johnson & Johnson to face UK class action lawsuit over talc asbestos claims November 9, 2022 Johnson & Johnson is set to face a class-action lawsuit brought forward by high-profile Houston litigator Mark Lanier’s new UK-based firm. The Houston litigator’s new law firm is launching a British class-action lawsuit against Johnson & Johnson over claims the New Jersey pharma giant’s talc products caused UK customers to develop cancer. The lawsuit is [...]
UK failing to capitalise on disease research as it lags behind Europe, says ABPI November 3, 2022 The UK is failing to capitalise on its world leading disease research, according to the country’s pharmaceutical body. The country could be unlocking significant economic benefits in better competing with its European rivals on genomics, the study of genomes which is crucial to understanding how diseases develop. In report published today by the Association of [...]
Aspire Pharma buys Morningstar healthcare divisions in undisclosed sum October 3, 2022 Aspire Pharma has bought Morningside’s pharmaceutical and healthcare divisions, as well as their subsidiaries for an undisclosed sum. The deal cements an ongoing post-pandemic trend of consolidation within the pharmaceutical and healthcare sectors. Morningside’s boss Tim Brady added that the deal will give Aspire access to over 120 mid and late-stage programs. Chief executive officer [...]
GSK snatches Julie Brown from Burberry’s top management September 24, 2022 GSK has reportedly snatched Burberry’s chief operating and financial officer Julie Brown. Sources told Sky News the £53bn pharmaceutical titan could appoint Brown as its chief financial officer as soon as Monday. The businesswoman in fact announced on Friday she would step down next year after six years at Burberry. Working alongside chief executive Dame [...]
Panic in pharma as bosses of four firms face being struck off: Shock CMA decision includes Alliance’s CEO September 2, 2022 Pharmaceutical firms have appealed against a competition case underlying the disqualifications of multiple industry bosses, which could potentially lead to the seven individuals being struck off. The Competition and Markets Authority (CMA) said on Friday that it had issued proceedings in the High Court to disqualify directors at four groups, including the chief executive of [...]
Raft of UK pharmaceutical directors risk being disqualified after CMA ruling September 2, 2022 The UK’s competition watchdog has today issued High Court proceedings to disqualify a raft of pharmaceutical directors, including Alliance Pharma’s CEO, over suspected anti-competitive agreements. The Competition and Markets Authority (CMA) launched the investigation into the UK’s pharmaceutical sector in 2017, and revealed earlier this year that several firms had been impeding competition in the [...]
Government must support UK science firms in shouldering cost pressures, says ABPI president August 25, 2022 The Government must help paint a positive picture for the pharmaceutical industry via increased support, so that CEOs feel encouraged to shoulder the cost pressures hitting the sector, the president of the Association of British Pharmaceutical Industry (ABPI) told City A.M. The industry is currently navigating staff shortages, inflation as well as dwindling investment, which [...]
Litigation over recalled drug weighs on GSK, Haleon and Sanofi stocks August 11, 2022 UK pharmaceutical stocks GSK, Haleon and Sanofi have been dragged into the red today – losing billions in market value – ahead of a litigation around recalled heartburn drug Zantac. GSK’s shares have fallen more nearly nine per cent, its newly listed spinoff firm Haleon sunk as much as seven per cent and Paris-based Sanofi [...]
UK competitions watchdog told to cover pharma firms’ costs after investigation failed May 25, 2022 The Supreme Court today said the UK’s Competition and Markets Authority (CMA) could be forced to cover Pfizer and Flynn Pharma’s legal costs, following the collapse of its case into the two pharmaceutical firms. The landmark ruling could see UK regulators made liable to pay the costs of those subject to failed investigations, after the [...]
Invidior unveils $100m share repurchase scheme with new drugs powering rebounding revenues April 28, 2022 Invidior has announced a $100 plan to return capital to shareholders, with the pharmaceutical firm on track to achieve its full-year guidance.